Your session is about to expire
← Back to Search
Study Summary
This trial is testing a new drug for atopic dermatitis (a skin condition). The study is comparing the new drug to a placebo, and looking at different doses of the drug to see what is most effective.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have been diagnosed with chronic atopic dermatitis for at least 1 year.It seems like there might be some information missing from your request. Could you please provide more details or clarify the criterion you would like me to summarize?You have severe eczema covering a large part of your body.You have a certain level of severity in eczema symptoms and affected skin area.You have had tuberculosis (TB) in the past or currently have evidence of TB infection.You have used a topical drug treatment in a way that didn’t work well or wasn’t right for your medical condition in the past 6 months.You have tested positive for hepatitis B, hepatitis C, or HIV.You have had a parasite infection in the past or have traveled to an area with a lot of parasites within the last 6 months.You haven't waited long enough after stopping certain medications before starting the study.You have had vernal or atopic keratoconjunctivitis in the last 6 months.You have had chronic atopic dermatitis (AD) for at least 1 year.You are 18 years old or older.You have not responded well to or have used topical medication in a way that wasn't recommended in the past 6 months.
- Group 1: AK120 Regimen 1
- Group 2: AK120 Regimen 2
- Group 3: Placebo to AK120
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many venues is this experiment being conducted at?
"This clinical trial is administered from numerous sites, including AkesoBio Investigative Site 2003 in Little Rock, Arkansas; AkesoBio Investigative Site 2021 in San Diego, California; and AkesoBio Investigative Site 2004 in Houston, Texas."
Does AK120 present any tangible risks to people who use it?
"The safety of AK120 has been rated as a 2, suggesting that there is evidence backing its general security but no proof yet proving its efficacy."
What is the maximum capacity of participants in this clinical study?
"To properly launch this clinical trial, 105 individuals that satisfy the established inclusion criteria are necessary. Akesobio Australia Pty Ltd will be spearheading the research from 2 sites: Little Rock's AkesoBio Investigative Site 2003 and San Diego's AkesoBio Investigative Site 2021."
Are there any available opportunities for individuals to partake in this clinical trial?
"Per clinicaltrials.gov, this trial is currently in its candidate recruitment stage. It was originally posted on September 30th 2021 and recently edited on July 4th 2022."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger